12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Latuda lurasidone: Phase III data

The double-blind, international Phase III PEARL 3 trial in 488 patients showed that once-daily 80 and 160 mg Latuda each met the primary endpoint of significantly reducing the PANSS total score from baseline to week 6 vs. placebo (22.2 and 26.5, respectively, vs. 10.3 points; p<0.001 for both). Low- and high-dose Latuda also met the secondary endpoint of significantly reducing CGI-S scores from baseline to week 6...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >